Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $30 at Cantor Fitzgerald
September 26, 2018 9:33 AM EDTCantor Fitzgerald analyst Elemer Piros raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to $30.00 (from $23.00) while maintaining an Overweight rating. The new price target is a 'Street High'.
Prios commented, "We are reiterating our OW rating and raising our 12-month PT to... More
Aldeyra Therapeutics (ALDX) Set to Up Higher by 60% Following Positive Results from Phase 2b Dry Eye Disease Clinical Trial
September 26, 2018 7:33 AM EDTAldeyra Therapeutics (NASDAQ: ALDX) Set to Up Higher by 60% Following Positive Results from Phase 2b Dry Eye Disease Clinical Trial
... More